Vera Therapeutics (VERA) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free VERA Stock Alerts $38.50 +0.48 (+1.26%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 10 at 1:20 AM | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of "Buy" from BrokeragesVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has received an average rating of "Buy" from the eight research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, six have issued a buy recommendation andJune 9 at 5:22 AM | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Rafferty Asset Management LLCRafferty Asset Management LLC boosted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 25.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 170,758 shares of the company's stockJune 8 at 4:00 PM | marketbeat.comSectoral Asset Management Inc. Has $1.91 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Sectoral Asset Management Inc. trimmed its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 65.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,151 shares oJune 8 at 5:48 AM | americanbankingnews.comVera Therapeutics (NASDAQ:VERA) Shares Gap Down to $41.18June 7 at 4:05 PM | globenewswire.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 7 at 4:05 PM | globenewswire.comVera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 5, 2024 | americanbankingnews.comVera Therapeutics (NASDAQ:VERA) Shares Up 6.7% After Analyst UpgradeJune 2, 2024 | americanbankingnews.comVera Therapeutics (NASDAQ:VERA) PT Raised to $65.00 at JPMorgan Chase & Co.May 31, 2024 | marketbeat.comJPMorgan Chase & Co. Increases Vera Therapeutics (NASDAQ:VERA) Price Target to $65.00JPMorgan Chase & Co. raised their target price on shares of Vera Therapeutics from $60.00 to $65.00 and gave the stock an "overweight" rating in a research note on Friday.May 28, 2024 | markets.businessinsider.comVera Therapeutics Says FDA Grants Breakthrough Therapy Designation For Atacicept To Treat IgANMay 28, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Gap Up to $37.11Vera Therapeutics (NASDAQ:VERA) Shares Gap Up to $37.11May 28, 2024 | globenewswire.comVera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)May 25, 2024 | globenewswire.comVera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association CongressMay 24, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Trading 5.3% Higher Vera Therapeutics (NASDAQ:VERA) Shares Up 5.3%May 20, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Gap Down to $41.39Vera Therapeutics (NASDAQ:VERA) Shares Gap Down to $41.39May 16, 2024 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Buy" by BrokeragesShares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have earned a consensus rating of "Buy" from the eight analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one hasMay 13, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Down 1.9% Vera Therapeutics (NASDAQ:VERA) Trading Down 1.9%May 10, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Issues Earnings ResultsVera Therapeutics (NASDAQ:VERA - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.03).May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vera Therapeutics Amid Promising Clinical Developments and Strong Financial PositionMay 9, 2024 | investorplace.comVERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024May 9, 2024 | msn.comVera Therapeutics GAAP EPS of -$0.56May 9, 2024 | globenewswire.comVera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | globenewswire.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 6, 2024 | finance.yahoo.comVera Therapeutics, Inc.'s (NASDAQ:VERA) high institutional ownership speaks for itself as stock continues to impress, up 5.0% over last weekMay 2, 2024 | markets.businessinsider.comIncyte’s Resilient Demand and Strong Financials Justify Buy Rating Despite Q1 Sales DipMay 1, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Trading 6.5% Higher Vera Therapeutics (NASDAQ:VERA) Trading Up 6.5%April 15, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Down 3% After Insider SellingVera Therapeutics (NASDAQ:VERA) Shares Down 3% Following Insider SellingApril 14, 2024 | investing.comVera Therapeutics executive sells over $228k in company stockApril 14, 2024 | marketbeat.comVanguard Group Inc. Raises Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Vanguard Group Inc. raised its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 9.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,574,390 shares of the company's stock after puApril 13, 2024 | insidertrades.comInsider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Sells 5,714 Shares of StockApril 13, 2024 | fool.comCould This Stock Be the Next Biotech Buyout?April 12, 2024 | finance.yahoo.comInsider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...April 12, 2024 | marketbeat.comJoseph R. Young Sells 5,714 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) StockVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) SVP Joseph R. Young sold 5,714 shares of the company's stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $40.00, for a total value of $228,560.00. Following the sale, the senior vice president now owns 53,171 shares in the company, valued at approximately $2,126,840. The sale was disclosed in a filing with the SEC, which is available through the SEC website.April 11, 2024 | msn.comBiotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores OptionsApril 10, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Stock Price Up 7.2%Vera Therapeutics (NASDAQ:VERA) Stock Price Up 7.2%April 10, 2024 | msn.comAlpine Immune jumps on report of takeover interestApril 8, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Gap Down on Insider SellingVera Therapeutics (NASDAQ:VERA) Shares Gap Down Following Insider SellingApril 8, 2024 | insidertrades.comVera Therapeutics, Inc. (NASDAQ:VERA) CFO Sells $3,954,187.08 in StockApril 7, 2024 | nasdaq.comCommit To Buy Vera Therapeutics At $25, Earn 12.7% Annualized Using OptionsApril 6, 2024 | marketbeat.comSean Grant Sells 99,828 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) StockVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CFO Sean Grant sold 99,828 shares of the business's stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $39.61, for a total value of $3,954,187.08. Following the completion of the sale, the chief financial officer now owns 66,337 shares in the company, valued at $2,627,608.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.April 5, 2024 | marketbeat.comGuggenheim Reiterates Buy Rating for Vera Therapeutics (NASDAQ:VERA)Guggenheim reiterated a "buy" rating and set a $56.00 price objective on shares of Vera Therapeutics in a research note on Friday.April 3, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Down 5.9% Vera Therapeutics (NASDAQ:VERA) Shares Down 5.9%April 3, 2024 | seekingalpha.comVera Therapeutics: Waiting For A PullbackMarch 29, 2024 | marketbeat.comWellington Management Group LLP Takes $1.16 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Wellington Management Group LLP bought a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 84,506 shares of the company's stock, valued atMarch 27, 2024 | marketbeat.comGuggenheim Raises Vera Therapeutics (NASDAQ:VERA) Price Target to $56.00Guggenheim boosted their target price on Vera Therapeutics from $27.00 to $56.00 and gave the stock a "buy" rating in a research report on Wednesday.March 26, 2024 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line DataMarch 26, 2024 | insidertrades.comInsider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) Director Sells 340,000 Shares of StockMarch 26, 2024 | insidertrades.comVera Therapeutics, Inc. (NASDAQ:VERA) Director Maha Katabi Sells 81,009 SharesMarch 21, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Trading Down 7%Vera Therapeutics (NASDAQ:VERA) Stock Price Down 7%March 21, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) PT Raised to $34.00Wedbush boosted their price target on Vera Therapeutics from $21.00 to $34.00 and gave the stock a "neutral" rating in a research report on Thursday. Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. VERA Media Mentions By Week VERA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERA News Sentiment▼0.650.76▲Average Medical News Sentiment VERA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERA Articles This Week▼73▲VERA Articles Average Week Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Legend Biotech News Today Ascendis Pharma A/S News Today Cerevel Therapeutics News Today Intra-Cellular Therapies News Today Jazz Pharmaceuticals News Today Blueprint Medicines News Today Viking Therapeutics News Today Ionis Pharmaceuticals News Today Cytokinetics News Today Summit Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERA) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored